Natalizumab and HSV meningitis

Erica Seiguer Shenoy, Eleftherios Mylonakis, Rocio M. Hurtado, Nagagopal Venna

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) is a monoclonal antibody approved for use in patients with relapsing multiple sclerosis (MS) as well as moderate to severe Crohn's disease. We report the first case of a patient with a history of MS, on monthly natalizumab, who developed HSV-2 meningitis. We discuss the mechanism of action of natalizumab and review what is known about the reactivation of herpes infection in association with this medication. The question of herpes simplex virus (HSV) and varicella zoster virus (VZV) prophylaxis for patients is raised.

Original languageEnglish (US)
Pages (from-to)288-290
Number of pages3
JournalJournal of NeuroVirology
Issue number3
StatePublished - Jun 2011

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Virology


Dive into the research topics of 'Natalizumab and HSV meningitis'. Together they form a unique fingerprint.

Cite this